Guardant Health Inc (GH)
🔔 Watch stock
symbol.quality_heading
We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.
Red is not for the price and not for the losses alone, but for two documented findings about substance. First, equity is used up: the balance sheet as of March 31, 2026 heads the section "Stockholders' Deficit" and shows negative $181.1 million, on an accumulated deficit of $3.1 billion and operating cash outflow in every year since inception. Second, 27 percent of quarterly revenue hangs on a single payer whose billing has been the subject of a False Claims Act investigation since April 22, 2026 — with no quantifiable exposure and no accrual. Plenty stands on the other side: a regulatory head start, 48 percent growth, a 65 percent gross margin, $1.1 billion of liquidity and no going concern warning. That does not make the company bad — it makes it a company whose substance currently depends on a reimbursement decision and a government file. In case of doubt the more cautious level applies. The decision is yours.
symbol.quality_note
Guardant Health sells blood tests that find cancer before it hurts — Shield is the first blood test approved by the FDA for primary colorectal cancer screening. Revenue rose 48 percent to $301.7 million in the first quarter of 2026, and screening revenue alone jumped 633 percent. The bottom line still showed a loss of $112.1 million, equity is gone at negative $181.1 million, and a single payer accounts for 27 percent of revenue. On April 22, 2026 a U.S. Attorney asked for the billing records tied to that very payer. We read the filings line by line — and keep count of who ends up owning how much.
Read the analysis
Stock Watch
This analysis is as of July 26, 2026. Stock Watch will tell you what's changed at GH since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 29 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 162.00 $ — 93% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
Sells AIGuardant Health verkauft KI-gestützte Analytik als Teil seines Angebots: Die GuardantINFORM-Plattform für biopharmazeutische Kunden wurde laut Geschäftsbericht mit KI-gestützten Analysewerkzeugen entwickelt und steht in der Umsatzzeile „Biopharma and data“, der Guardant-Tissue-Test enthält ein KI-gestütztes PD-L1-Ergebnis, und das gesamte Produktportfolio läuft laut Quartalsbericht über die Smart Platform mit der hauseigenen InfinityAI-Lernmaschine.
View the full file — quotes, sources, reviewed filings
„Our product portfolio is now powered by our Smart Platform, which utilizes methylation technology with genomic, epigenomic, and RNA-based data, to unlock multi-modal biology with proprietary chemistry, advanced algorithms and our InfinityAI learning engine."
Unser Produktportfolio wird inzwischen von unserer Smart Platform angetrieben, die Methylierungstechnologie mit genomischen, epigenomischen und RNA-basierten Daten nutzt, um mit eigener Chemie, fortgeschrittenen Algorithmen und unserer InfinityAI-Lernmaschine multimodale Biologie zu erschließen.
„Using data collected from our tests and through AI-enabled analytical tools, we have also developed our GuardantINFORM platform to help biopharmaceutical companies accelerate precision oncology drug development"
Aus den Daten unserer Tests und mithilfe KI-gestützter Analysewerkzeuge haben wir zudem unsere GuardantINFORM-Plattform entwickelt, um biopharmazeutischen Unternehmen zu helfen, die Medikamentenentwicklung in der Präzisionsonkologie zu beschleunigen
„we offer Guardant Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis, including DNA, RNA, AI-powered PD-L1 and genome-wide methylation data"
wir bieten Guardant Tissue an, den ersten Molekularprofil-Test für Tumorgewebe, der eine umfassende Multiomics-Analyse einschließt — darunter DNA, RNA, KI-gestütztes PD-L1 und genomweite Methylierungsdaten
Filings Reviewed: 10-Q 2026-05-07 · 10-K 2026-02-19 · 10-Q 2025-10-29 · 10-Q 2025-07-30 · 10-Q 2025-04-30 · 10-K 2025-02-20
Rated on July 26, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 15.7% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 23
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.43 | -1.81 – -1.09 | 1,348 | 21.3% | 20 |
| 12/31/2027 | -0.44 | -1.43 – 0.71 | 1,801 | 69.2% | 18 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.90 | – | 202 | 30.20 | -55.00 | -65 | -83 |
| 2025: Q1 | -0.77 | – | 204 | 20.80 | -46.80 | -63 | -67 |
| 2025: Q2 | -0.80 | – | 232 | 30.90 | -43.00 | -60 | -66 |
| 2025: Q3 | -0.74 | – | 265 | 38.50 | -35.00 | -35 | -46 |
| 2025: Q4 | -1.00 | – | 281 | 39.40 | -45.70 | -14 | -42 |
| 2026: Q1 | -0.85 | – | 302 | 48.30 | -37.20 | -66 | -71 |
| 2026: Q2 | -0.90 | -12.50 | 335 | 44.30 | -35.90 | -58 | -70 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 25 | -44 | -46 | -3.49 | -37 | 80 | 117 |
| 2017 | 50 | -77 | -83 | -1.18 | -72 | 309 | 343 |
| 2018 | 91 | -93 | -85 | -1.00 | -72 | 483 | 587 |
| 2019 | 214 | -82 | -76 | -0.84 | -47 | 798 | 963 |
| 2020 | 287 | -255 | -254 | -2.60 | -104 | 1,299 | 2,272 |
| 2021 | 374 | -411 | -406 | -4.00 | -209 | 645 | 2,205 |
| 2022 | 450 | -544 | -655 | -6.41 | -309 | 60 | 1,610 |
| 2023 | 564 | -565 | -479 | -4.28 | -325 | 159 | 1,786 |
| 2024 | 739 | -444 | -436 | -3.56 | -240 | -140 | 1,486 |
| 2025 | 982 | -437 | -416 | -3.32 | -185 | -99 | 2,014 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Assessment: Opportunities & Risks
According to the Form 10-Q as of March 31, 2026, Shield is the first blood test approved by the FDA for primary colorectal cancer screening and the first to meet Medicare's coverage requirements; it also appears in the NCCN screening guidelines. Guardant360 CDx was the first comprehensive liquid biopsy approved by the FDA for tumor mutation profiling. Those regulatory head starts are documented and cannot be copied quickly.
Revenue rose from $373.7 million in 2021 to $982.0 million in 2025 and climbed 48 percent to $301.7 million in the first quarter of 2026. Screening grew 633 percent in that quarter to $41.6 million on roughly 44,000 tests versus roughly 9,000 a year earlier; oncology added 36 percent to $205.0 million. The pace increased in 2026 rather than fading.
There has been no profitable year since the 2018 IPO: a net loss of $405.7 million in 2021, $654.6 million in 2022, $479.4 million in 2023, $436.4 million in 2024, $416.3 million in 2025 and $112.1 million in the first quarter of 2026. In that quarter sales and marketing expense grew 62 percent to $169.1 million, faster than revenue at 48 percent; gross profit of $196.7 million faced operating costs of $318.1 million.
Equity is used up: negative $181.1 million as of March 31, 2026 against positive $645.0 million at the end of 2021, with an accumulated deficit of $3.1 billion. Against that sit $1,102.8 million of cash and short-term securities and $1,493.2 million principal of convertible notes, the first tranche of which — $490.7 million — matures on November 15, 2027. There is expressly no going concern warning; the most recent funding came from an equity offering at $90.00 per share in November 2025.
A single payer accounted for 27 percent of revenue in the first quarter of 2026 (28 percent in 2025, 31 percent in 2023). On April 22, 2026 Guardant received a civil investigative demand from the U.S. Attorney for the Southern District of Florida under the False Claims Act, aimed at billing to federally funded health insurance programs. Neither an amount nor an accrual is disclosed; the company says it cannot predict the outcome.
The quarterly report shows 28.466 million potential share equivalents as of March 31, 2026, of which 16.465 million come from the convertible notes — roughly 22 percent of the 131.273 million weighted-average shares. On top of that, 32,075,509 shares are reserved for employee programs, and an at-the-market program of up to $400.0 million stands ready, from which no share had been sold by that date. Transparently reported, but material in size.
Guardant Health is the halo trap in its purest form: the medicine is unarguably good, the business behind it is not automatically good too. What is documented is growth that is accelerating — up 48 percent to $301.7 million in the first quarter of 2026, with screening up 633 percent — alongside a 65 percent gross margin and $1,102.8 million in cash and securities. Equally documented: no profit since inception, an accumulated deficit of $3.1 billion, equity of negative $181.1 million and a single payer behind 27 percent of revenue — whose billing has been under examination by a U.S. Attorney since April 22, 2026. The market pays roughly 18 times a year of revenue for that. Not investment advice.
- Guardant Health landed on the research list through our in-house stock scanner: rank 21 of 28 in the list "Richard Moglen: 1 Week Top Performers" (U.S. selection) with a relative strength rating of 92, as of July 25, 2026. That list is recomputed daily; it measures price momentum over four trading days, liquidity and relative strength — demand for the shares, not quality of the company.
- Every figure carries its own reporting date: annual figures from the Form 10-K for 2025 (filed February 19, 2026), quarterly figures from the Form 10-Q as of March 31, 2026 (filed May 7, 2026). Valuation metrics as of July 26, 2026 based on the closing price of July 24, 2026 — meant to be evergreen, with no daily price used as a buy argument. The status of the legal proceedings is that of the quarterly report of May 7, 2026; no Form 8-K reporting an outcome was filed between then and July 26, 2026.
- Easy to confuse: the ticker GH belongs to Guardant Health, Inc. of Palo Alto (CIK 0001576280), not to the same letters on other exchanges. The SEC registration lists no former company names. Guardant should also not be confused with rival Natera, against which it won a trial in November 2024, or with Tempus AI, with which two proceedings run in opposite directions.
About the Company
Guardant Health, Inc. ist ein Präzisionsonkologie-Unternehmen, das Blut- und Gewebetests sowie Datensätze in den USA und international anbietet.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 2,490 |
| Headquarters | Palo Alto, CA |
| Address | 3100 Hanover Street, 94304 Palo Alto, United States |
| Phone | 855 698 8887 |
| Website | guardanthealth.com |
| IPO Date | 4. Oct 2018 |
| ISIN | US40131M1099 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Helmy Eltoukhy Ph.D. | Co-Founder, Co-CEO & Chairman | 1979 |
| AmirAli Talasaz Ph.D. | Co-CEO & Director | 1980 |
| Michael Bell | Chief Financial Officer | 1969 |
| Darya Chudova | Chief Technology Officer | 1974 |
| John G. Saia J.D. | Chief Legal Officer & Corporate Secretary | 1973 |
| Andy Ament | Senior Vice President of Operations | – |
| Kumud Kalia | Chief Information Officer | 1966 |
| Zarak Khurshid | Vice President of Investor Relations | – |
| Gulshan Shaver J.D. | Senior VP of Legal Affairs & Chief Compliance Officer | – |
| Jennifer Higgins | Senior Vice President of Public Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 21. Jul 2026 | Mignone Roberto | Director | Other | 264 | 0.00 | – |
| 17. Jul 2026 | Hidalgo Medina Manuel | Director | Other | 232 | 0.00 | – |
| 16. Jul 2026 | Tariq Musa | Director | Sell | 116 | 163.29 | 18,942 |
| 15. Jul 2026 | Tariq Musa | Director | Other | 250 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.